Member Info for JamestheBard

Sub £14m valuation with near USD3bn resource.

Seems mismatched now Mali is open for business again.

Reuter reporting Barrick dispute is resolved. If so it will free up a lot of mining officials to move onto other business, like Cora. Barrick pay Mali circa USD 450m pa so they put a lot of focus and resource towards that first .

Haleon Brand range by late 2026 / mid 2027 COULD contain

Eroxon

Eroxon Intense

Eroxon for women

Eroxon Intense for Women

IF so Haleon may wish to protect their position and Brand image by absorbing FUM.

VLG has a compelling growth model. There is excess manufacturing capacity and so identify and purchase a product ie Earol, shut down the existing manufacturing arrangements and bring it to VLG facility. That increases profit margins and rewards the purchase. The strong cashflow repays the purchase price quickly.

Credit Rivaldo 5th Feb post of where to research further for originals. Need to register with Ca&£ndish.

Sure Slater are focusing on future value of multiples of EPS, actual / forecasts:

2024 4.4p

2025 6.3p

2026 7.7p

2027 9.5p

Additionally whilst these are too far out for my liking, once VLG own brands have grown it is probable that VLG will be absorbed by a bigger player allowing Slater to cash out.

With solid support stakeholders there only seems to be sub £5m at this MCAP for private investors to ' fight' over in a 1 000 000 oz resource at usd 2900 oz.

Mine production expected circa 60000oz pa at say AISC USD 1000, allowing some leeway provides USD 100M profitability for 16 years.

Q4 2025 Eroxon Intense, minimal change to production,packaging and distribution arrangements so expectations for availability rapidly throughout early 2026. Consequently immediate manufacture and sell in to stock up all existing retailers giving strong pick up in 2026 revenues.

BOD rejected higher offers from other potential partners based on Haleons huge ambitions to invest heavily and build usd100m+ annual revenue. The logic being that over time a far greater revenue will be achieved for FUM overall.

Haleon have a clear target to make Eroxon a brand category in the US. They have stated that this requires annual revenue of USD 100m+ and usd 20 or 30m will not sustain a brand long term. They have also been clear that as it is a new category they cannot give guidance on how long it will take. So follow Haleon for news particularly analyst Q&As.

WSD 4000 BOD were awaiting Home user study data along with market research data before deciding on a commercialisation strategy. Discussions with potential partners were ongoing. From RNS and pipeline section on FUM webpage so not market sensitive. So discussions are underway for a partner. Should an existing partner have ambitions to develop a significant brand range then that partner may wish to assist and guide the development at an early stage this time. A commercial deal could come at the beginning for WSD 4000 rather than the end.

Eroxon Intense will generate initial stocking up orders again, to get the addition to the product range on the shelves next to Eroxon. As it is encompassed within existing commercial agreements, consider the impact on future milestone payments.

Walgreens US reviews 5 star 256, 4star 113, 3star 102, 2star 68, 1star 176. Total 721. For Eroxon 4 tubes USD 29.99

Overall 3.3/5

Amazon US still at 20000 units plus per month and Eroxon presently part of a limited offer promotion of buy 2 from a group of products and get 30% off one.

Boots buy one pack of Eroxon £24.99 and get one half price. Proof of marketing effort.

Eroxon Intense covered by existing commercial agreements, WSD4000 not so and commercial discussions were stated as ongoing, RNS 4th Nov 24.

2025 loss is now forecast but those estimates will include expenses required for EU and FDA trials for Eroxon intense and whatever costs will be associated towards progress with WSD 4000.